• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
186173 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

/ Z7 u" _( S  R+ S% ?* m可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  + ~! ~8 ]# ?( R0 Y
% H8 _9 `! t. e

& ~: W8 ]7 b! Z7 B0 L5 |& aSub-category:8 `* @, \2 ^% p4 w$ E1 o  x" U. W
Molecular Targets ( U1 \: {$ L8 A  I+ v
" u7 W& X' q) A2 h" P- [
7 L" u, @8 M3 b# i1 N
Category:+ {! q# R+ J- F
Tumor Biology % `4 N9 J* Y% h9 Z/ n  @
3 Z4 c  Y2 `% |+ v8 S3 c$ l2 B

9 |5 [+ v. f3 D4 z7 KMeeting:0 @2 v6 |9 k& s: G. E+ x
2011 ASCO Annual Meeting ( t4 [# s5 m) g. A* Y6 p/ m
( v4 C) e2 q6 [" m. [
5 P5 B) z9 `, A0 y/ G$ W" N6 m
Session Type and Session Title:
- l- N) F* ~. c2 j- d7 wPoster Discussion Session, Tumor Biology
* v8 Q9 S1 R- Z% M9 ^/ b, K- z9 ?' a. {, b, F

& Y* I1 K4 N! z8 r# kAbstract No:
. d2 U- V2 O  V) V% D: w6 u10517 2 d# `. G7 |' \4 u4 e9 K' {5 o
( E; v0 a- u1 J/ _$ T2 k) |0 [" t! P$ K

" D( p6 \- r) O& l4 Y6 F" L) \) tCitation:5 l- E) c7 N/ F' v
J Clin Oncol 29: 2011 (suppl; abstr 10517)
1 B5 Q5 Q2 t4 p: {% {" W5 `  L4 v* H, r$ ~3 g

* @8 `5 l( m1 `* l1 k5 V* Y) x/ `Author(s):
$ N' X& `/ o# }- x! ]# Q+ xJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 \4 C) d0 L) ?* C1 u+ A/ `, j
( B5 H$ Y# ?7 f$ H9 Z, O, A4 y, F+ G( f8 M

0 L' j) d8 B9 ?+ dAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
8 w. g9 N  |9 E9 }) C  [2 w; ^9 w0 U! ]2 @6 L" I4 v1 p4 H  }
Abstract Disclosures/ e2 r  |1 R4 Z& o; H5 n
" o: ]0 e) X7 g1 K+ q
Abstract:# w  N3 F1 r& ~  {+ S1 V8 W

& `8 K" T0 F# x
. @' X% g. ?7 q6 W5 k& i& R5 }/ T* [1 IBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.. I+ H+ H, h/ p( F
5 X) K- f' E& \! V
0 S: E1 b% z$ d* n1 W$ E
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ! M2 h  H, `( I
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
4 C7 c2 W( ]% o0 V# V
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 # w. a7 k1 q% c% _, \2 \$ x3 {
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。; }5 \9 c+ \+ Z- Y. p
ALK一个指标医院要900多 ...
% p7 c- `, N8 _+ D+ W6 G
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?; B# ^4 j5 }0 Z" f+ k$ ?; M' U
, Q! Y1 o- y: N3 A4 s
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表